The word matched does a great deal of unexamined work in this market. It appears on quotes, in capability decks and in conversations, and it very rarely comes with the one qualifier that determines whether it means anything: the resolution behind it. Two donors can be described as matched by one supplier and mismatched by another, both accurately.
Resolution is the whole claim
HLA typing is reported in colon-separated fields of decreasing scope. The first field is the allele group, which corresponds roughly to the old serological antigen. The second identifies a distinct protein. Matching at the first field is antigen-level matching. Matching at the second is allele-level, usually called high resolution.
| Antigen-level | Allele-level | |
|---|---|---|
| Compares | First field only | At least the first two fields |
| Typical method | Serology or low-resolution PCR | Sequencing |
| Ambiguity | Common | Resolved |
| Two donors called matched here | May differ in protein sequence | Share the protein |
| Adequate for allogeneic work | Rarely | Yes, and it is the current expectation |
Two donors described as antigen-matched can be allele-mismatched, and the difference is immunologically real. When a supplier says matched, the useful next question is at which field, by which method.
Reading match fractions
Fractions such as 8/8 and 10/10 count matched alleles across a defined set of loci, both inherited copies included. An 8/8 covers HLA-A, B, C and DRB1. A 10/10 adds DQB1. The fraction is only interpretable once you know which loci are in the denominator and at what resolution they were compared, which is why a bare fraction on a quote is close to uninformative.
Not all mismatches carry equal weight either. Permissive mismatches exist, particularly at DPB1, where a mismatch may be tolerated in a way that a mismatch elsewhere would not be. Treating all loci as equivalent produces both unnecessary donor exclusions and misplaced confidence.
What matching is for in an allogeneic program
Matching addresses two directions of immune recognition. Recipient immunity against the product drives rejection and limits persistence. Product immunity against the recipient, where the material contains competent T cells, drives graft-versus-host disease. How much matching a program needs depends on which of those dominates, and on whether the effector type carries the second risk at all.
This is why NK-based approaches attract allogeneic interest. NK cells carry a markedly lower graft-versus-host risk than T cells, which changes the matching calculus entirely. The underlying biology is covered in the NK cell guide, and the donor-side variable that matters most for NK work is KIR rather than HLA alone.
Building a panel rather than finding a match
Most programs do not need one matched donor. They need a defined set of donors, characterized at high resolution, that can be returned to over the life of the program.
A panel supports comparability work, lets you hold HLA constant while varying something else, and gives you a population against which to interpret donor-driven variance. A single matched donor supports one experiment and then becomes a supply problem.
Specifying it properly
A workable specification names the loci that matter to the program, states the required resolution, distinguishes hard constraints from preferences, and says whether the requirement is one donor or a panel with continuity. It should also state what else has to travel with the type, because HLA alone is rarely the only relevant attribute. Cytomegalovirus status, KIR genotype and donor age frequently matter alongside it.
OrganaBio documents high-resolution NGS genotyping across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP with KIR genotyping, applied at donor program level rather than per order, which is what allows selection by genotype rather than filtering of inventory, subject to availability. Eligible donors can be scheduled for repeat collection. Nomenclature and method detail sit in the HLA typing guide, and the underlying biology in the HLA system. Material spans leukopaks, PBMCs and isolated T and NK populations from the same donors.
Frequently asked questions
What does HLA-matched actually mean?
It depends entirely on resolution. Antigen-level matching compares only the first field of the allele name. Allele-level or high-resolution matching compares at least the first two fields and identifies the specific protein. Two donors called antigen-matched can be allele-mismatched, so the resolution behind the claim is the claim.
What does an 8/8 or 10/10 HLA match mean?
It counts matched alleles across a defined set of loci including both inherited copies. An 8/8 covers HLA-A, B, C and DRB1; a 10/10 adds DQB1. The fraction is only interpretable once you know which loci are in the denominator and at what resolution they were compared.
Are all HLA mismatches equally important?
No. Permissive mismatches exist, particularly at DPB1, where a mismatch may be tolerated in a way that a mismatch at another locus would not be. Treating every locus as equivalent produces both unnecessary donor exclusions and misplaced confidence.
Why do NK-based allogeneic programs need less HLA matching?
Because NK cells carry a markedly lower graft-versus-host disease risk than T cells, which removes one of the two directions of immune recognition that matching normally has to address. For NK work, KIR genotype read against target HLA class I is often the more informative donor variable.
Should I source one matched donor or an HLA-defined panel?
Most programs are better served by a panel. A panel supports comparability, lets you hold HLA constant while varying something else, and gives a population against which to interpret donor-driven variance. A single matched donor supports one experiment and then becomes a supply problem.
What should an HLA specification include?
The loci that matter to the program, the required resolution, a clear separation of hard constraints from preferences, whether one donor or a panel with continuity is needed, and any attributes that must travel alongside the type such as cytomegalovirus status, KIR genotype or donor age.
Can I get material from the same HLA-typed donor again later?
That depends on whether the supplier operates a repeat-collection program rather than selling from finite banked inventory. Ask specifically whether named donors can be returned to over a defined period and what would prevent it, since recall is scoped per program rather than guaranteed.
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
